London, April, 2017: Private equity fund manager Calculus Capital has closed its EIS fundraising after reaching its £20m target three months earlier than anticipated. John Glencross, Calculus Capital Chief Executive, said: “Appetite for investing in unlisted UK smaller companies through the Enterprise Investment Scheme has been growing year-on-year. And it’s not surprising, given the breadth, depth … Continued
March 20, 2017. FT adviser. John Glencross, CEO, Calculus Capital writes: The rewards from enterprise Investment Scheme (EIS) funds and Venture Capital Trusts (VCTs) are often considerable, but many would argue so too are the risks. These highly tax-efficient vehicles are therefore not suitable for all investors, with analysis showing that as many as half … Continued
Successful Clinical Results for Genedrive® HCV Assay External Validation Studies Show Sensitivity of Greater Than 99% and Specificity of 100% for Hepatitis C Assay Designed for Decentralised Use in Resource Limited Settings genedrive plc, the near patient molecular diagnostics company, announced that it has successfully completed clinical validation studies to support a submission for CE … Continued
Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist Calculus Capital has invested in Collagen Solutions Plc (AIM: COS), a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. Calculus invested £1 million as part of an open offer of approximately £6.83 … Continued
Calculus Capital’s portfolio company Inspiresport have joined forces with Manchester City FC in an exclusive partnership to bring schools and clubs a brand new promotional video. This promotional video forms part of the overall strategy to give overseas children the opportunity to train at this world-class facility, and is directly available on the Manchester City FC … Continued
Private equity fund manager and Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist Calculus Capital has invested £4.75m in Park Street Shipping, which purchases and operates second-hand dry bulk vessels.Calculus set up Park Street Shipping in conjunction with Clarksons, the world’s leading provider of integrated shipping services, and Nordic Hamburg, a technical manager which … Continued
Calculus Capital portfolio company Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a partnership with a major international diagnostics services group to implement the IONA® test in at least two laboratories. Premaitha, through its distribution network, has secured a four-year Master Procurement Agreement (the “MPA”) with a major … Continued
As trampoline parks spring up all over the country, Oliver Astley from the Guardian looks into the new craze and features Calculus Capital’s portfolio company Jumptastic. The gate opens and about 100 children, and a handful of adults, fan out and start bouncing as if their tops were made out of rubber and their bottoms … Continued
Arcis Biotechnology announced its success in winning £160,000 from Innovate UK’s Biocatalyst programme to fund a new research programme into extracting and stabilising ribonucleic acid (RNA) direct from urine to help clinical diagnostic testing. The funding will be used to assess the technical feasibility of extracting and stabilising RNA direct from urine, for use in … Continued
Calculus Capital, the private equity fund manager and Enterprise Investment Scheme and VCT specialist, has been named Best EIS Manager in the Enterprise Investment Scheme Association (EISA) Awards. It is the third consecutive year, and the fifth in total, that Calculus has received the award, which was announced last night (February 1) in a ceremony … Continued